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Abstract 
 
Background 
While short-term psychodynamic psychotherapies have been shown effective for major depression, it is 
unclear if this could be a treatment of choice for depressed patients who have not sufficiently responded to 
existing treatments and commonly have chronic and complex health issues. 
Method 
This superiority trial used a single blind randomised parallel group design to test the effectiveness of time-
limited Intensive Short-Term Dynamic Psychotherapy (ISTDP) for treatment resistant depression (TRD). 
Patients referred to secondary care community mental health teams (CMHT) who met DSM-IV criteria for 
major depressive episode, had received antidepressant treatment t6 weeks, and had Hamilton Depression 
Rating Scale (HAM-D) scores of t 16 were recruited. The effects of 20 sessions of ISTDP were judged 
through comparison against secondary care CMHT treatment as usual (TAU).  The primary outcome was 
HAM-D scores at 6 months. Secondary outcomes included dichotomous measures of both remission 
(defined as HAM-D score d 7) and partial remission (defined as HAM-D score d 12).  
Results 
Sixty patients were randomised to 2 groups (ISTDP=30 and TAU=30), with data collected at baseline, 3, and 
6 months. Multi-level linear regression modelling showed that change over time on both depression scales 
was significantly greater in the ISTDP group in comparison to TAU. Statistically significant between-group 
treatment differences, in the moderate to large range, favouring ISTDP, were observed on both the observer 
rated (&RKHQ¶Vd = 0.75) and self-report measures (&RKHQ¶Vd = 0.85) of depression. Relative to TAU, 
patients in the ISTDP group were significantly more likely after 6 months to achieve complete remission 
(36.0% vs. 3.7%) and partial remission (48.0% vs. 18.5%).   
Limitations 
It is unclear if the results are generalizable to other providers, geographical locations and cultures. 
Conclusions  
Time-limited ISTDP appears an effective treatment option for TRD, showing large advantages over routine 
treatment delivered by secondary care services. 
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Introduction 
 
Depression is among the largest single causes of disability worldwide, and the disease burden of depression 
is on the rise globally (Murray and Lopez, 1997; WHO, 2013). Anti-depressant treatment is considered a 
first line agent for major depression. However, up to half of patients do not show a satisfactory response, and 
up to 20% do not benefit from multiple treatment courses (Kubitz et al., 2013). With every failed treatment 
the SDWLHQW¶Vlong-term prognosis deteriorates (Rush et al., 2006). Where adequate treatment dose and 
duration were applied, such cases are termed treatment resistant depression (TRD). Despite a lack of clear 
guidance on effective treatments when depression does not remit with first line medication (MacQueen et al., 
2017; Malhi et al., 2009), it is more common to change medication than commence psychotherapy 
(Markowitz, 2008). This may be due to insufficient empirical evidence demonstrating the efficacy of 
psychotherapy for this complex population. A 2011 review of psychological treatments found only 6 trials 
(Trivedi et al., 2011) and 3 subsequent randomised controlled trials (RCTs) reported mixed findings. In one 
trial, cognitive behavior therapy as an adjunct to pharmacotherapy in primary care was found to be superior 
to general practitioner care as usual (Wiles et al., 2013). In another, long-term psychoanalytic psychotherapy 
was shown to be efficacious when compared to primary care treatment as usual (Fonagy et al., 2015) 
demonstrating that long-term therapies can contribute to the understanding of TRD. In contrast, a third RCT 
found no benefit of adding interpersonal psychotherapy to pharmacotherapy and clinical management 
(Souza et al., 2016).  
 
Short-term psychodynamic psychotherapies (STPPs) are widely used, having been found as effective for 
reducing depressive symptoms as other first-line psychological treatments (Connolly-Gibbons et al., 2016; 
Driessen et al., 2013). While the effectiveness of STPPs has been demonstrated for depression (Connolly-
Gibbons et al., 2016; Driessen et al., 2015) and in the setting of comorbid personality disorder (Abbass et al., 
2011) the relevance of STPPs to patients with TRD is less clear. A pilot study of Intensive Short-Term 
Dynamic Psychotherapy (ISTDP), one of the STPP models, found preliminary evidence that the TRD sub-
population of depressed patients can benefit from this approach (Abbass, 2006).  
 
Given the paucity of empirical support for all psychotherapies with this population, this study formally 
examines the efficacy of ISTDP for TRD using a controlled trial. To provide an ecologically valid 
comparison, the effect of ISTDP was compared to that of secondary care Community Mental Health Teams 
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(CMHTs) which served as a treatment as usual (TAU) control. We hypothesized a linear decrease over time 
in patients¶observer-rated and self-reported depression during the course of treatment and, critically, that 
this decrease would be greater in patients receiving ISTDP compared to TAU.  
 
Methods 
Study Design 
This superiority trial used a single blind randomised parallel group design to examine the efficacy of ISTDP, 
in comparison with secondary care TAU provided by CMHTs, for depressed patients who were non-
remitting following at least 1 course of antidepressant treatment. The primary indicator of effectiveness was 
the reduction of depressive symptoms, measured by the Hamilton Depression Scale (HAM-D) (Hamilton, 
1967). The study protocol was registered with ClinicalTrials.gov (ID: NCT01141426) and approved by the 
Nova Scotia Health Authority Research Ethics Board (NSHA-RS/2013-049). 
 
Sample Size Calculation 
Pre-study power calculations utilized information from a pilot study (N=10) for TRD (Abbass, 2006), and 
meta-analysis (Driessen et al., 2010) with equivalent psychotherapy treatment (STPPs) for depression and 
using similar outcome instruments. The pilot yielded a very large within-group effect of ISTDP at post-
WUHDWPHQW&RKHQ¶Vd t 2.0) but it was not compared to TAU. The meta-analysis suggested a conservative 
prediction was to estimate a large pre- to post-treatment effect measured by HAM-'&RKHQ¶Vd t 1.0) 
following ISTDP (Driessen et al., 2015) and small-to-PHGLXP&RKHQ¶Vd § 0.30) following TAU (Murray et 
al., 2010). Therefore, assuming an average between-group effect size of d = 0.70, a significance level of 
alpha = .05 and 2 groups of participants, a sample of 68 participants was required to achieve 80% power. 
However, due to delays in sample recruitment, only 60 participants were recruited. 
 
Participant Eligibility and Recruitment  
7KHVWXG\¶V&216257GLDJUDPLVSUHVHQWHGLQfigure 1. Between September 2012 and March 2015, 143 
potential participants were referred to the study by clinicians from 4 secondary care outpatient CMHTs 
based in Halifax Regional Municipality, Nova Scotia, Canada. Patients eligible to be referred were 
outpatients, aged 18-65 years, with a primary diagnosis of major depressive disorder according to DSM-IV 
criteria.  
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Of 143 patients referred, 120 could be contacted to conduct a more detailed assessment of their eligibility for 
the study. DSM-IV diagnoses were assessed at baseline using the Mini Neuropsychiatric Interview-Plus 
(M.I.N.I. plus) (Sheehan et al., 1992) and the Structured Clinical Interview for DSM-IV Axis II Personality 
disorders (First et al., 1997) by a research assistant and research psychologist respectively. Both were trained 
for the study purposes and were blinded to treatment allocation. Patients met study criteria for TRD by 
having had at least one trial of antidepressants at the adequate recommended therapeutic dose; a current 
depressive episode duration of 6 or more weeks; inadequate response to treatment (assessed by 17-item 
HAM-D score t 16); not having started further medication or changed dose of existing medication in the 
previous 6 weeks; and not having received treatment in the previous 2 years at any of the 4 CMHTs. 
 
Patients were excluded if they had psychotic depression, bipolar depression, severe substance dependence or 
cognitive impairment, severe cluster A personality disorder, active suicidality or self-mutilating behavior 
that would require significant modifications to treatment; or if their depressive disorder was due to a general 
medical condition or secondary to a comorbid mental health or psychosocial condition; or they were unable 
to give informed consent to treatment.  
 
,QIRUPDWLRQRQSDUWLFLSDQWV¶DQWLGHSUHVVDQWKLVWRU\ZDVREWDLQHGIURPLQGLYLGXDOJHQHUDOSUDFWLWLRQHUVDQG
through review of medical electronic records. This information was reviewed by a psychiatrist to quantify 
level of treatment resistance using the Thase and Rush 5-Stage Model (TR-S) (Thase and Rush, 1997) and 
the Massachusetts General Hospital Staging Model (MGH-S) (Fava, 2003). Of the 120 patients assessed, 60 
did not meet inclusion criteria or declined participation and were excluded.  
 
Randomisation and Allocation 
Screening assessments and enrollment were conducted by research assistants who remained blind throughout 
the randomisation and allocation process. Allocation was then conducted at the end of enrollment by an 
administrative assistant. Patients were allocated to ISTDP or secondary care TAU in a 1:1 ratio (i.e. 30 
patients randomly assigned to each group). For purposes of randomisation a researcher external to the study 
team generated a permuted block randomisation sequence using a digital random number generator. 
 
Intervention Protocol 
Intensive Short-Term Dynamic Psychotherapy.  
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The ISTDP model is a brief psychotherapy format that helps the patient identify and address the emotional 
factors that culminate into, exacerbate and perpetuate depression. ISTDP is tailored to the patLHQW¶Vanxiety 
WROHUDQFH:KHUHQHFHVVDU\WKHWKHUDSLVWXVHVDVXSSRUWLYH³JUDGHGIRUPDW´WREXLOGHPRWLRQDOFDSDFLWLHV, 
and introduces elements to assist the cessation of emotional avoidant behaviors as seen in session 
(clarification and challenge to defenses).  The ultimate goal is an active engaged therapy process that builds 
the patients¶ awareness and capacity to experience emotions that adversely affect their mood. 
 
The number of ISTDP sessions provided for common mental health problems varies according to case 
severity (typically with an upper limit of 40 applied). Once the nature of the difficulties has been established 
in the extended trial therapy session, the therapist may estimate an approximate number of sessions required, 
though the exact duration of treatment is not agreed upon. For this study however, ISTDP was provided 
according to a 20-session time-limited, individual format to allow comparisons with other manualized time-
limited psychotherapy models. The treatment was delivered according to a manual and published 
recommendations (Abbass, 2015; Davanloo, 2000). The first session was an extended 2-3 hour appointment; 
subsequent hourly sessions were scheduled every week. Any planned termination before 20 sessions was 
based upon agreement between therapist and patient.  
 
Treatment was delivered by 4 therapists (1 psychiatrist, 3 clinical psychologists) on average treating 7 
patients each. The distribution of number of cases seen by individual therapists was 2, 5, 8, 13. Allocation of 
cases was determined by therapist availability. All clinicians were licensed professionals with supervised 
experience practicing ISTDP (mean experience = 10.25 years, range= 4-20 years). All therapists participated 
in a half-day course on TRD and, for the duration of the trial, met on a weekly basis to review and discuss 
videotaped treatment sessions. Additionally, a study supervisor provided access to weekly case supervision 
using a review of video recordings of treatment: at least 1 session per quartile of treatment was reviewed. 
 
Medication Management  
The study sought to minimize confounding effects of pharmacotherapy treatments that may alter the 
comparative impacts of ISTDP and TAU, whilst balancing the need to promote treatment adherence. 
According to the study inclusion criteria of non-remittance of depressive symptoms following at least 1 
course of antidepressant, a patient remains symptomatic despite the use of any existing medications. A 
ISTDP for treatment resistant depression 
 7 
medication washout phase was therefore not specified in the protocol prior to treatment allocation to avoid 
possible withdrawal and subsequent treatment effects.  
 
For participants receiving ISTDP it was requested that medications remain stable. 3DUWLFLSDQWV¶JHQHUDO
practitioners (GP) were contacted to monitor medication, and participants were advised to discuss 
medication with their GP. Participants in the ISTDP group unable to follow the medication protocol were not 
excluded, but detailed information was collected on medication changes. For participants receiving TAU, 
pharmacotherapy was described as one of the possible treatment approaches that could be offered by a 
CMHT. Pharmacotherapy treatment strategies consisted of individualized regimes informed by Canadian-
based clinical guidelines for managing major depression (Lam et al., 2009). 
 
Secondary care treatment as usual (TAU)  
At each CMHT site, TAU consisted of a multidisciplinary team approach including pharmacotherapy and 
clinical management, supportive or structured activities focused around symptom management and, in some 
cases, individual or group psychotherapy. TAU was not regulated, thus facilitating a naturalistic assessment 
of standard secondary care treatment delivery - except that trial participants were not offered ISTDP during 
the trial. Therapeutic interventions were expected to be heterogeneous: hence, details on doses and 
approaches delivered to each participant were obtained and documented. 
 
Outcome Measures  
Outcome assessments were conducted at baseline, mid-treatment (prior to session 11) and post-treatment in 
the ISTDP group. TAU group patients likewise followed this assessment schedule; however, this occurred at 
pre-defined time-points selected to match the measurement schedule in the ISTDP group, specifically 
baseline, 3 months, and 6 months following enrolment. 
 
The primary measure of participants¶ depressive symptomology was the observer-rated 17-item HAM-D 
(Hamilton, 1967). A research assistant was trained to use a standardized clinical interview to administer this 
structured rating system designed to assess symptom severity of individuals with a clinical diagnosis of 
depression disorder (Bech et al., 2003). During training 3 clinical interviews were rated by the evaluator and 
ratings FRPSDUHGZLWKDQH[SHUW¶VUDWLQJV Research assistants were blind to treatment condition; and to 
maintain concealment patients were instructed to refrain from discussing their treatment during assessments. 
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All interviews were videotaped to assess rating reliability. At regular intervals during the study, the evaluator 
met with an independent experienced evaluator (clinical psychologist) to review and discuss videotaped 
interviews to prevent rater drift. In total, 26 HAM-D assessments were independently rated by both 
evaluators and the average intraclass correlation coefficient was 0.96. Internal consistency of the HAM-D 
was high for 2 of the 3 time-pointVWLPH&URQEDFK¶VDOSKD = .617; time 2, alpha = .841; time 3, alpha = 
.849). 
 
Our secondary outcome was patient-rated depression, measured by the scale sum score from the 9-item 
Patient Health Questionnaire (PHQ-9) (Kroenke and Spitzer, 2002). Internal consistency of this measure was 
high at all 3 time-points (alpha = .783, alpha = .899, alpha = .912 respectively). For a series of 
supplementary analyses we also converted the sum score versions of the HAM-D and PHQ-9 scales to 
binary outcomes representing full and partial remission. For the purposes of this study, µEHLQJLQremission¶ 
was defined as achieving a HAM-D score of d 7, and µat least partial remission¶ being reflected by a HAM-
D score of d 12. For the PHQ-9 measure, remission was defined as achieving a scale sum score of d 4, and at 
least partial remission by achieving a score d 9. The results from additional secondary outcome measures 
will be published in a follow-up manuscript. 
 
Treatment Integrity 
To assess treatment integrity of the ISTDP intervention, the Comparative Psychotherapy Process Scale 
(CPPS) (Hilsenroth et al., 2005), a validated measure with distinct psychodynamic-interpersonal (PI) and 
cognitive behavioral (CB) subscales, was selected for characterizing therapist interventions according to a 
psychodynamic model compared to a cognitive-behavioral model. For every participant treated using 
ISTDP, sessions 1, 4, 10 and 16 (representing trial therapy, early, mid and late treatment phases) were 
watched and evaluated in their entirety by 2 independent researchers (evaluators). Evaluators were blind to 
the session number.  All evaluators attended 24 hours of training in using the CPPS to establish their 
reliability in scoring; during training, 10 psychotherapy tapes were independently rated by evaluators and 
scores compared with pre-established expert ratings. All evaluators demonstrated satisfactory inter-rater 
reliability prior to data collection. In order to minimize the drift in the accuracy of scoring of treatment 
sessions, evaluators discussed coding with the CPPS instructor at regular intervals. Having independently 
rated sessions, evaluators participated in a consensus discussion to generate an agreed rating for each 
session: a third rater was consulted where necessary.  
ISTDP for treatment resistant depression 
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Treatment provided by secondary care CMHTs was selected to provide an ecologically valid TAU condition. 
Secondary care TAU was therefore unregulated to provide a naturalistic comparison group and therapeutic 
interventions were expected to be heterogeneous. Due to the range of interventions available, formal 
treatment integrity ratings were therefore not conducted; however, treatment received was well documented.  
 
Statistical Analyses 
We first investigated whether the demographic and clinical characteristics of the sample differed between 
intervention and control groups, using independent groups t-tests, Mann-Whitney U-tests, or chi-square tests 
as appropriate, enabling us to identify if we needed to control for any potential confounding demographic 
effects in the subsequent hypothesis testing. 
 
To compare the impact of ISTDP and TAU on participants¶ depressive symptoms, as measured by the 
HAM-D and PHQ-9 scale sum scores across the 3 time-points, longitudinal multilevel linear regression 
modelling was used (Singer and Willet, 2003). The multilevel modelling approach to longitudinal data, in 
which data is arranged at the observation (i.e. time-point) level, is advantageous in maximising the sample 
size, and enabling the distinction between outcome variance to be explained at subject and observation levels 
as well as modelling within-subject auto-correlations across time. For modelling diagnostic versions of the 
HAM-D and PHQ-9, logistic generalized estimating equations (GEEs) (Twisk, 2004; Zeger and Liang, 
1986), which also model the data at the observation level were used. GEEs were preferred to logistic 
multilevel models due to their greater stability (Driessen et al., 2013). 
 
For both HAM-D and PHQ-9 sum score outcomes, five models were fitted in sequence, to quantify extent 
and variation in change in depression over time, and then assess how this variability was explained by 
treatment differences. First, an unconditional model (with no predictors) assessed baseline levels of within 
and between-subject variation, and model fit (Model Deviance).  Second, time-point (coded 0 = start of 
treatment, 1 = 3 months after baseline, 2 = 6 months after baseline) was added as a predictor, testing our 
initial hypothesis of a linear decrease in depression across the study period (having controlled for 
demographic variables associated with study group, if any were found). Third, a random effect of time-point 
was added, to estimate between-subject variation in any such change. The potential correlation between 
intercept and slope was examined and retained if it improved model fit, though given the random allocation 
into treatment groups there was no expectation that starting level of depression would covary with any 
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change due to treatment differences. Fourth, the main effect of study group was added. Finally, to assess 
whether any between-subject variation in change in depression was due to treatment (our primary 
hypothesis), the interaction between time-point and group was added. An autoregressive type1 (AR1) 
autocorrelation structure was tested in conjunction to this final model in an attempt to explain any further 
variation.  
 
As well as testing the fixed interaction effect of time by group (i.e. whether change in depression differs 
between ISTDP and TAU groups), simple slopes estimates from the final model were tested to ascertain 
ZKHWKHUWKHLPSDFWRIHDFKWUHDWPHQWZDVGLIIHUHQWIURPµQRFKDQJH¶LQV\PSWRPV For the supplementary 
analyses of diagnostic outcomes, a single GEE model was fitted for each outcome, simultaneously testing 
the main effects of, and interaction between time and treatment group. 
 
SPSSv21 was used, with multilevel analyses performed using the MIXED function, with Maximum 
Likelihood estimation used to fit the models; sequential models were compared by testing the change in the 
Deviance i.e. -2*log-likelihood. GEE analyses were performed using the GENLIN function. Mplusv7.4 
software was used to calculate simple slopes tests, estimated marginal means, corresponding post-hoc tests 
and effect sizes. For all analyses, the p < 0.05 level of statistical significance was applied; using two-tailed 
tests, and Bonferroni-corrected where appropriate given the testing of multiple related outcomes. 95% 
confidence intervals and effect sizes (variance explained at each level) are reported. Analyses and reporting 
are in accordance with Consolidated Standards of Reporting Trial guidelines (Moher et al., 2010). 
 
Adverse Events 
Adverse events during the trial occurred in two participants in the TAU group who reported increases in 
depressive symptoms. None were judged to be related to study intervention. Statistical tests of difference 
were not conducted due to the small number of participants with adverse events.   
 
Results 
 
Sample Description and Treatment Completion 
The majority of participants in the sample scored within the severe range on the HAM-D alongside 
comorbid mental health disorders and chronic physical illness; 96.7% had a comorbid Axis I disorder; 89.7% 
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fulfilled criteria for Axis II personality disorder; 90.9% had current longstanding physical illness or 
disability. A relatively high rate of participants (63.8%) had failed at least two pharmacotherapy trials from 
two distinct antidepressant classes for the current major depressive episode. Table 1 summarises 
demographic and baseline clinical characteristics of the participants. No significant differences in 
demographic and clinical characteristics were found between the treatment conditions. The 60 randomised 
SDUWLFLSDQWVZHUHLQFOXGHGLQRXUSULPDU\µLQWHQWLRQWRWUHDW¶DQDO\VLVVDPSOH2IWKHSDUWLFLSDQWV
randomised to ISTDP, the mean number of sessions completed was 16.1 (SD = 6.68). Twenty-four (72%) 
participants received at least 15 sessions; 1 completed treatment after 5 sessions due to symptom remission; 
2 dropped out of the study immediately after randomisation due to work commitments; 1 dropped out after 1 
session, and 2 more dropped out after 8 sessions, again due to work commitments. Table 2 summarises the 
treatment received within the experimental and comparison condition. In the control group (TAU), 29 
participants (97%) received at least one session of talking therapy (mean number of sessions = 7.6, SD = 
3.7). The one-to-one therapy delivered by CMHTs was primarily counseling (57%) or CBT (40%). In 
addition, 15 participants (50%) received group therapy within a structured 10-12 two-hour session CBT 
format. Participants receiving TAU were more likely (&2 = 13.017, p < .001) to have pharmacotherapy 
increased or changed than those in the ISTDP group (53% vs. 10%). Participants receiving ISTDP were 
more likely (&2 = 26.447, p < .001) to stop or reduce pharmacotherapy treatments (67% vs. 3%) 
 
Due to the aforementioned drop-out and a handful of non-completed measures, our analysis sample 
consisted of 167 responses from 60 participants, with complete data at time-point 1 (baseline), 55 responses 
at time-point 2, and 52 at time-point 3. Forty-nine participants responded at all 3 time-points. The missing 
data was distributed equally between the two groups and there were no significant differences in attrition 
rates between the groups. 
 
Treatment Integrity 
To examine the treatment integrity of the ISTDP intervention, a total of 100 sessions were rated using the 
CPPS (Hilsenroth et al., 2005); recordings were not available for 3 sessions. Mean inter-rater reliability 
values (as measured by the intraclass correlation coefficient type 1) for the PI and CB scales were 0.92 and 
UHVSHFWLYHO\IDOOLQJLQWKHµH[FHOOHQW¶UDQJHt 0.75) according to standardized recommendations 
(Shrout and Fleiss, 1979).  
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The consensus rating across treatment sessions on the PI scale (mean = 2.44, SD = 0.89) was greater than for 
the CB scale (mean = 0.72, SD = 0.26): i.e. consistent with the treatment protocol, ISTDP videotapes were 
rated as more characteristic of a psychodynamic therapy than a cognitive-behavioral model (t = 21.40, p 
<.0001). Furthermore, in line with our a priori expectation that ISTDP sessions would be better 
characterized by specific PI interventions focused on emotional experiencing rather than interpretative 
intervention, the highest item mean scores were recorded by PI item-³7KHWKHUDSLVWHQFRXUDJHVWKHSDWLHQW
WRH[SHULHQFHDQGH[SUHVVIHHOLQJVLQWKHVHVVLRQ´DQG3,LWHP-³7KHWKHUDSLVWHQFRXUDJHVWKHH[SORUDWLRQ
RIIHHOLQJVUHJDUGHGE\WKHSDWLHQWDVXQFRPIRUWDEOHHJDQJHUVDGQHVV´ 
 
Outcomes 
Continuous HAM-D and PHQ-9 measures 
Sample mean scores for HAM-D and PHQ-9 sum scores of patients in each study group are provided in 
figures 2 and 3. For both of these outcomes, introducing a linear effect of time to the model produced a 
statistically significant improvement in model fit compared to the unconditional model (table 3, model 2). 
The effect of time was significant and negative (HAM-D: B = -3.876, p < 0.05; PHQ-9: B = -3.258, p < 
0.05) indicating that the incidence of depressive symptoms decreased over time. Allowing the effect of 
change over time to vary between subjects (table 3, model 3) further improved the model fit, indicating that 
participants were showing different rates of improvement in depressive symptoms; however there was no 
indication that improvement was significantly related with initial level of symptoms (hence the intercept-
slope covariance was fixed at zero for subsequent analyses).  
 
Adding the interaction effect between time and study group again significantly improved the model fit (table 
3, model 5; adding an autoregressive type1 within subjects correlation structure did not improve model fit, 
hence this was not retained). Unexplained variation in change over time was reduced by 18.5% for HAM-D, 
and by 25.4% for PHQ-9. The interaction effect was significant and negative (HAM-D: B = -2.704, p < 0.05; 
PHQ-9: B = -2.677, p < 0.05). For both outcomes, a simple slopes test indicated that the decrease in 
symptoms was significant for both groups; however, decreases for the ISTDP intervention group was just 
over twice as steep as for the TAU control group (HAM-D: -5.313 vs. -2.609; PHQ-9: -4.659 vs. -1.982). 
Post-hoc tests, simple slopes tests and simple effect sizes relating to the predicted between-group differences 
at each time-point from this final model are presented in table 4. 
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These results support our primary hypothesis that ISTDP yields DJUHDWHULPSURYHPHQWLQSDWLHQW¶VZHOO-
being relative to standard treatments. In addition, the assumption of sustained linear change appears more 
clearly justified for the ISTDP group: the sample mean scores (figures 2 and 3) demonstrate the efficacy of a 
linear model for decrease in depressive symptoms over the course of treatment with ISTDP, even over this 
short period of treatment. 
 
Diagnostic HAM-D and PHQ-9 measures 
The results found for the continuous versions of the HAM-D and PHQ-9 are mirrored by their diagnostic 
counterparts, albeit with effects less pronounced (due to the use of blunter dichotomous diagnostic measures 
as opposed to continuous scales). The sample percentages achieving full and partial remission using the 
HAM-D or PHQ-9-based diagnostic thresholds varied widely by group (e.g. HAM-D full remission, ISTDP 
36% vs. TAU 3.7%; HAM-D partial remission, ISTDP 48.0% vs. TAU 18.5%; PHQ-9 full remission, 
ISTDP 32.0% vs. TAU 4.3%; PHQ-9 partial remission, ISTDP 60.0% vs. TAU 8.7%). When modelling 
these diagnostic outcomes, we found significant interactions between treatment group and time-point, with 
the odds of partial and full remission diagnoses showing a significantly greater increase over time for 
patients treated with ISTDP as opposed to TAU, thus supporting our hypothesis. Specifically, the odds of 
partial remission from HAM-D diagnosed symptoms per each additional time-point were over 2.5 times 
greater for the ISTDP group (exp(B) = 2.799, p < 0.05); for partial remission, the odds increased to over 3 
times greater (exp(B) = 3.373, p < 0.05). The estimated odds of partial remission from PHQ-9 assessed 
symptoms were almost 5 times greater for the ISTDP treated group for each additional time-point (exp(B) = 
5.278, p < 0.05). Only for the full remission criterion from PHQ-9 assessed symptoms was a significant 
difference between treatments not found. Full details of these models are presented in table 5. 
 
Discussion 
 
The Halifax Depression Study RCT examined the efficacy of time-limited ISTDP for secondary care 
patients presenting with TRD. Improvements in both observer and patient rated depression scores for those 
receiving ISTDP were greater than for patients receiving TAU. The observed benefits of individuals with 
TRD receiving ISTDP as a front line alternative to routine treatment also included patients being more likely 
to reach remission on the primary measure of depression. 
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The definition of TRD requires participants to have tried at least 1 adequate antidepressant dose for 6 weeks. 
Like other recent psychotherapy trials (Souza et al., 2016; Wiles et al., 2013), we chose this pragmatic 
definition to be representative of a heterogeneous and difficult-to-treat population commonly requesting care 
at secondary care CMHTs. While there is no standard universally accepted definition or criteria of TRD, the 
number and type of prior antidepressant medication failures may be considered an indication of degree of 
TRD. Nevertheless, using the less conservative inclusion threshold of at least 1 failed antidepressant, we 
found that two-thirds of the recruited sample had failed to respond to an adequate trial of pharmacotherapy 
from two distinct antidepressant classes (Thase and Rush, 1997) and over half (56%) had received past 
psychotherapy treatment. When the intensity and optimization of each prior failed antidepressant treatment 
was taken into consideration using the MGH-S staging model (Fava, 2003), degree of resistance score 
indicated multiple unsuccessful treatment efforts. Furthermore, we were struck by the level of chronicity and 
complexity found in the current sample: for example, participants reported on average 4 previous depressive 
episodes, alongside extremely high rates of severe depression (80%), long-term medical illness (90.7%), axis 
I comorbidity (96.6%) and axis II comorbidity (89.7%).  
 
These observations suggest that in cases of unremitting clinical depression presenting to secondary care 
services, treatment resistance simply defined based on a categorical approach of at least 1 medication failure, 
is likely to include patients with multiple risk factors that predict poorer treatment prognosis (Thase et al., 
2001). Of note, a significant majority of patients in the current sample fulfilled criteria for personality 
disorder, a proportion (15%) of which were cluster B personality disorder. The relative efficacy of the 
treatment protocols evaluated in this study could therefore have been confounded by the use of a mood 
disorder approach for some participants with symptoms of affective instability and rejection sensitivity 
(Choi-Kain and Rodriguez-Villa, 2015). These findings highlight the challenges faced in clinical practice 
and have implications for the design of healthcare services as it suggests that treatment approaches for major 
depression need also be tailored to personality-disordered patients.  
 
There are few published RCTs examining the effectiveness of psychotherapy for TRD (Trivedi et al., 2011). 
To our knowledge this is the first using a STPP model. ISTDP outcomes clearly outperformed those from 
the TAU condition, in which over half of patients changed or augmented antidepressant medications, and 
many received talking therapy in combination. This result is particularly notable based upon the relatively 
intensive interventions received in the TAU condition. These findings contribute to the evidence for 
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psychodynamic treatments for depression. The Halifax Study replicates previous results (Wiles et al., 2013) 
suggesting that time-limited psychotherapy is an alternative first line treatment strategy for TRD that 
significantly improves the odds of remission compared to routine CMHT treatments provided. Based on the 
chronic and often relapsing nature of TRD, we are planning to examine long-term outcomes to assess 
whether improvement is sustained and maintained. The study conclusions should also consider that the 
between-group difference in efficacy could be a non-specific treatment effect related to ISTDP participants 
receiving on average a greater dose of therapy. When the effectiveness of different manualized 
psychotherapy treatments for TRD has been examined, where the number of available sessions, training and 
supervision were comparable, no differences been treatments were found (Kocsis et al., 2009). The same is 
true for other psychiatric disorders when bona-fide psychotherapies are directly compared (Wampold and 
Imel., 2015). Future research therefore remains necessary in naturalistic settings that compare the delivery of 
manualised psychotherapies to TAU involving comparable doses of psychotherapeutic services. 
 
With the exception of the Sequenced Treatment Alternative to Relieve Depression (STAR*D) study (Thase 
et al., 2007), evidence from clinical trials for TRD have previously tested the effects of psychotherapy 
treatment in combination with antidepressant augmentation/changes. In contrast, the Halifax Study 
attempted to isolate and study the additional benefit of psychotherapy as a treatment alternative by 
requesting that existing antidepressant medications remained stable in the ISTDP group. This appeared 
acceptable to participants receiving ISTDP in that only 1 person requested antidepressant augmentation 
during treatment and, compared to TAU, significantly more participants stopped or reduced medications 
during treatment. Furthermore, the 36% full remission rates at the end of ISTDP in the Halifax Study is 
comparable to the remission rates reported in other trials (21.0-38.5%) (Kocsis et al., 2009; Souza et al., 
2016; Thase et al., 2007; Wiles et al., 2013). To test the effectiveness of ISTDP as an augmentation strategy 
for TRD it should be delivered alongside antidepressants and compared against a control group receiving the 
same medication algorithm.  
 
Short-term psychodynamic models, such as ISTDP, overlap with Long-Term Psychoanalytic Psychotherapy 
(LTPP) in the use of common techniques such as focusing on the relationship (transference) between the 
WKHUDSLVWDQGSDWLHQWDQGDQHPSKDVLVRQPHPRULHVDQGIHHOLQJVUHODWHGWRWKHSDWLHQW¶VHDUO\H[SHULHQFHV
The Tavistock Depression Study (TADS) tested LTPP as an adjunct to TAU for TRD (Fonagy et al., 2015). 
Although remission at the end of the 18-month treatment was uncommon in both groups (e.g., LTPP 
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remission 9.4%), at 2 years post treatment the observed decrease in depression scores had continued and was 
significantly greater in the LTPP group (LTPP remission 14.9% at 42-month follow-up). In comparison to 
the percentage of participants who achieved complete remission after a 6-month ISTDP treatment (36%), 
these remission rates suggest that symptom change may be possible after relatively fewer sessions of 
psychodynamic therapy. Such variation in observed rates of response may have implications for service 
utilization and thus, for the cost effectiveness of treatment. It will be important that future research can assist 
stakeholders for public health providers in understanding which patients can benefit from brief therapy and 
which require long-term therapy. 
 
We considered the Halifax Study design a relatively stringent test of the real world effectiveness of the 
experimental treatment, based on several factors including: the recruitment of refractory patients determined 
to need secondary care services; random allocation to an active treatment comparison provided by secondary 
care CMHTs; use of blinded outcome ratings; and a time-limited treatment protocol that also requested no 
DXJPHQWDWLRQRIFXUUHQWDQWLGHSUHVVDQWPHGLFDWLRQVLQWKHH[SHULPHQWDOJURXS:KLOH,67'3WKHUDSLVWV¶
adherence to general psychodynamic technique was measured by trained independent assessors, focal 
adherence to model specific techniques was not formally examined. Therapists had however all received 
substantial training in ISTDP and there was ongoing supervision using audio-visual session recordings of 
treatment in order to promote treatment credibility. The quality of treatment was likely representative of 
what could be expected from a small but established clinic specializing in this form of talk therapy.  
 
Study limitations include the following issues. First, this is a single blind RCT because therapists and 
patients could not be blinded to treatment allocation. The knowledge alone of being in receipt or not of the 
experimental treatment could have influenced outcomes through an expectancy effect. Second, this was a 
single centre study, with the experimental treatment delivered by one clinical team; thus, it is unclear if the 
results are generalizable to other providers, geographical locations and cultures. It is noticeable that there is 
no ethnic diversity within the recruited sample. Third, this project was conducted by proponents of the 
experimental treatment which increases the likelihood of an allegiance effect (Luborsky et al., 1999), a 
phenomenon that has been shown to lead to an overestimation of treatment effects in psychotherapy 
effectiveness research (Baldwin and Imel, 2013). We attempted to minimize this through selecting the 
observer-rated HAM-D as the primary outcome measure and ensuring administration by an independent 
assessor blinded to treatment allocation.  
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Conclusions 
 
Moderate to large effects, favouring ISTDP relative to secondary care mental health team care, were 
observed following 6 months of treatment in a sample with TRD. Like other treatments for TRD, an 
unsatisfactory number of patients who received time-limited ISTDP did not reach the desired goal of full 
remission and required further treatment. Future research needs to better understand why this was the case 
and if therapy could have been optimized, extended or medically augmented to facilitate remission. It is our 
intention to explore the degree to which presumed processes underlying therapeutic change in ISTDP (e.g., 
patient emotional processing) were present in sessions and second, if variation in putative variables predicted 
change in depressive symptoms. 
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Figure 1. CONSORT Diagram of patient flow through Halifax Depression Study 
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Table 1: Demographic variables and clinical characteristics by experimental group 
 
 ISTDP (N= 30) TAU (N=30) TOTAL (N=60) 
Demographic Variables Mean SD Mean SD Mean SD 
Age (years) 38.900 11.868 44.200 12.240 41.550 12.248 
       
 N % N % N % 
Male 13 43.3% 9 30.0% 22 36.7% 
Caucasian 30 100.0% 28 93.3% 58 96.7% 
Married 14 46.7% 9 30.0% 23 38.3% 
Living with one or more person 23 76.7% 21 70.0% 44 73.3% 
In employment 21 70.0% 18 60.0% 39 65.0% 
University Education 22 73.3% 19 63.3% 41 68.3% 
 
      
Clinical Characteristics Mean SD Mean SD Mean SD 
HAM-D-17 sum score, baseline  23.500 5.309 24.033 5.169 23.767 5.202 
PHQ-9 sum score, baseline 19.167 4.639 20.300 4.843 19.733 4.737 
N of previous episodes of depression  3.655 1.717 4.200 1.400 3.932 1.574 
MGH score 4.810 2.667 4.089 2.077 4.456 2.402 
       
 Median IQR Median IQR Median IQR 
Duration present depressive episode (mths) 24.0 75.0 36.0 87.0 30.0 81.0 
N of different antidepressants previously 
taken in lifetime 
3.0 2.0 3.0 2.5 3.0 2.0 
       
 N % N % N % 
HAM-D-17 severe/very severe depression 
(sum score > 18) 
24 80.0% 24 80.0% 48 80.0% 
PHQ-9 severe depression (sum score > 19) 14 46.7% 18 60.0% 32 53.3% 
Any current co-morbid Axis I disorder 28 93.3% 30 100.0% 58 96.7% 
Any current co-morbid Axis II disorder 25 86.2% 27 93.1% 52 89.7% 
Any current co-morbid Cluster B disorder  4 13.3% 5 16.7 9 15.0% 
Any current longstanding physical illness 
or disability 23 88.5% 27 93.1% 50 90.9% 
Any current co-morbid substance use 4 13.3% 3 10.0% 7 11.7% 
Lifetime history of receiving psychotherapy 14 46.7% 18 60.0% 32 53.3 
Two or more failed antidepressants for 
current episodeΐ 
12 40% 8 27.6% 20 33.9% 
TR-S scoreΐΐ:  Stage I 10 33.3% 11 39.3% 21 36.2% 
  Stage II 17 56.7% 11 39.3% 28 48.3% 
  Stage III-V 3 10.0% 6 21.4% 9 15.5% 
 
HAM-D = Hamilton Depression Scale. PHQ-9 = Population Health Questionnaire for Depression. MGH 
= Massachusetts General Hospital staging method (1 point per trial of adequate dose of antidepressant for 
t 6 weeks; 0.5 point per trial per optimization strategy). TR-S = Thase and Rush staging method (Stage 1: 
failure of at least 1 adequate trial of 1 major class of antidepressant; Stage 2: Stage 1 resistance plus 
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failure of adequate trial of an antidepressant in a distinctly different class from that used in Stage I; Stage 
III-V: Stage II resistance plus at least failure of an adequate trial of a TCA). Axis II disorder data collected 
using Structured Clinical Interview for DSM-IV Axis II personality disorders 
Total N/percentage base = 60, Group N/percentage base = 30, 30, except for:  

 N = 58, 29, 29;  N = 55, 29, 26; Á N = 59, 29, 30; ÁÁ N = 58, 28, 30 
 
 
 
Table 2: Treatment Received Summary 
 
 ISTDP 
(N=30) 
 TAU 
(N=30) 
Statistic p-value 
 
N (%)  N (%)   
Talking Therapy      
ISTDP (Mean N sessions) 16.1 (6.6)  0 F= 13.473 <.001*** 
Other Therapy (Mean N sessions)  0  7.6 (3.7) F= 11.340 <.001*** 
Other Therapy (%) 0  29 (96.7) F= 56.129 <.001*** 
CBT (%) 0  12 (40.0) F= 15.000 <.001*** 
Counselling (%) 0  17 (56.7) F= 23.721 <.001*** 
Group CBT (%) 0  15 (50.0) F= 20.000 <.001*** 
      
Other Interventions      
Guided Self-help (%) 0  2 (6.7) F= 2.069 .492 
Peer support group (%) 0  4 (13.3) F= 4.286 .112 
Meditation group (%) 0  2 (6.7) F= 2.069 .492 
Healthy living plans (%) 0  3 (10.7) F= 3.158 .237 
A&E urgent care (%) 0  3 (10.0) F= 3.158 .237 
Psychiatry (%) 1 (3.3)  8 (26.7) F= 6.405 .011* 
      
Medications      
Medications at T1:      
Antidepressants (%) 29 (96.7)  28 (93.3) F= .351 .554 
Anxiolytics (%) 13 (43.3)  11 (36.7) F= .278 .792 
Antipsychotics (%) 2 (6.7)  3 (10.0) F= .218 .640 
Hypnotics (%) 5 (16.7)  4 (13.3) F= .131 .718 
      
Medications T1 to T3:      
Medications added/changed (%) 3 (10.3)  16 (55.2) F= 13.228 <.001*** 
Medications stopped/reduced (%) 20 (66.6)  1 (3.3) F= 26.947 <.001*** 
T1 N of medications (mean/SD)  1.80 (1.10)  1.77 (.90) t = .129 .989 
T3 N of medications (mean/SD)  1.24 (1.12)  2.28 (.88) t = 3.901 .001*** 
 
Note: Statistical comparisons of differences between groups were conducted on proportions 
using the chi-square test and of means with Student t-tests. CBT- cognitive behavioral therapy; 
ISTDP- intensive short-term dynamic psychotherapy; TAU- treatment as usual 
*p<0.05, **p<0.01, ***p<0.001 
Total N/percentage base = 60, Group N/percentage base = 30, 30, except for:  N = 58, 29, 29 
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Table 3: Longitudinal multilevel models for HAM-D and PHQ-9 sum scores - model fit and 
improvement, fixed and random effects coefficients 
 
  Outcome 
Model Model fit and improvement (bold);  
Fixed Effects and 95% CIs;  
Random Effects and 95% CIs (italics),  
HAM-D continuous PHQ-9 continuous 
 
1 
 
Model Deviance (-2*Log-likelihood) 1142.446 1065.665 
 Residual (within-subjects) variance 41.681 31.808 
 Intercept (between-subjects) variance 21.110 16.573 
 
 
  
2 Model Deviance 1093.514 1024.050 
 Change in Deviance, df 48.932, 1* 41.615, 1* 
 Time-point B = -3.876* (-4.859, -2.894) B = -3.258* (-4.167, -2.350) 
 Residual variance 26.750 21.537 
 Intercept variance 25.513 19.554 
 
 
  
3 Model Deviance 1083.879 1009.434 
 Change in Deviance, df 9.635, 1* 14.616, 1* 
 Time-point B = -3.915* (-5.060, -2.770) B = -3.398* (-4.521, -2.275) 
 Residual variance 20.495 15.394 
 Intercept variance 17.644 11.392 
 Slope (Time) variance 7.673 8.385 
 
 
  
4 Model Deviance 1081.075 1005.386 
 Change in Deviance, df 2.804, 1 4.048, 1* 
 Time-point B = -3.925* (-5.050, -2.799) B = -3.381* (-4.477, -2.284) 
 Treatment (0 = TAU, 1 = ISTDP) B = -2.364 (-5.115, 0.387) B = -2.405* (-4.710, -0.100) 
 Residual variance 20.984 15.956 
 Intercept variance 16.676 10.137 
 Slope (Time) variance 6.813 7.367 
 
 
  
5 Model Deviance 1075.045 999.094 
 Change in Deviance, df 6.030, 1* 6.292, 1* 
 Time-point B = -2.609* (-4.105, -1.113) B = -1.982* (-3.451, -0.512) 
 Treatment (0 = TAU, 1 = ISTDP) B = -0.814 (-3.864, 2.236) B = -1.155 (-3.709, 1.399) 
 Time-point * Treatment B = -2.704* (-4.854, -0.555) B = -2.677* (-4.730, -0.624) 
 Residual variance 20.387 15.836 
 Intercept variance 17.664 10.979 
 Slope (Time) variance 5.553 5.499 
 
167 observations from 60 participants 
* p < 0.05 (2-tailed tests for fixed effects and model improvement, Bonferroni corrected)  
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Table 4: Group Differences / post-hoc tests for Estimated Marginal Means at Times 1, 2 and 3 (taken 
from Model 5), and corresponding effect sizes  
 
  Estimated Marginal 
Means 
Estimated mean 
difference 
 Effect Size 
Measure Time ISTDP TAU Difference SE Observed SD &RKHQ¶V' 95% CI 
HAM-D T1 23.031 23.845       0.814 1.533 5.202   
 T2 17.718       21.236       3.518* 1.443 8.075 0.436 (0.085, 0.786) 
 T3 12.405 18.627 6.223* 2.029 8.321 0.748 (0.270, 1.226) 
PHQ-9 T1 18.855       20.012       1.157 1.276 4.737   
 T2 14.196       18.026       3.830* 1.256 6.881 0.557 (0.199, 0.915)    
 T3 9.536 16.040       6.504* 1.911 7.793 0.835 (0.354, 1.315) 
 
Effect size computed using estimated marginal means, and the SD of the outcome variable from the 
observed data at the respective time-point.* p < 0.05 (2-tailed test, Bonferroni corrected) 
 
 
Table 5: GEE models for HAM-D and PHQ-9 diagnostic coding - model fit and regression 
coefficients, with sample percentages by group 
 
  Outcome 
Predictor Variable  HAM-D 
diagnostic: 
full remission 
HAM-D 
diagnostic: 
partial 
remission 
PHQ-9 
diagnostic: full 
remission 
PHQ-9 
diagnostic: 
partial  
remission 
Time-point B 
Odds Ratio (exp(B)) 
95% CI for exp(B) 
-0.006 
 0.994 
(0.961, 1.030) 
0.055 
1.056  
(0.598, 1.867) 
0.591 
1.806 
(0.453, 7.196) 
0.347 
1.415 
(0.598, 3.349) 
 
Treatment  
(0 = TAU,  
1 = ISTDP) 
B 
Odds Ratio (exp(B)) 
95% CI for exp(B) 
-0.570 
0.565 
(0.044, 7.247) 
-1.492 
0.225 
(0.038, 1.332) 
-2.366 
0.094 
(0.001, 12.883) 
-2.533 
0.079, 
(0.005, 1.238) 
 
Time-point * 
Treatment 
B 
Odds Ratio (exp(B)) 
95% CI for exp(B) 
1.216* 
3.373 
(2.443, 4.657) 
1.029* 
2.799 
(1.377, 5.691) 
1.427 
4.167 
(0.642, 27.058) 
1.663* 
5.278 
(1.701, 16.375) 
      
Model Fit (QIC)  87.667 155.288 77.656 117.558 
      
Sample %s 
showing remission 
by time 3 
ISTDP group: 
TAU group: 
 
36.0 
3.7 
 
48.0 
18.5 
 
32.0 
4.3 
 
60.0 
8.7 
 
 
167 observations from 60 participants 
* p < 0.05 (2-tailed test, Bonferroni corrected)  
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Figure 2: The 17-item HAM-D scale sample mean sum score by treatment group and time-point. 
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Figure 3: The PHQ-9 scale sample mean sum score by treatment group and time-point. 
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